Phibro Animal Health (PAHC)
(Delayed Data from NSDQ)
$19.65 USD
-0.22 (-1.11%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $19.63 -0.02 (-0.10%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth B Momentum A VGM
Income Statements
Fiscal Year end for Phibro Animal Health Corporation falls in the month of June .
All items in Millions except EPS data.
6/30/24 | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | |
---|---|---|---|---|---|
Sales | 1,018 | 978 | 942 | 833 | 800 |
Cost Of Goods | 705 | 680 | 657 | 562 | 543 |
Gross Profit | 313 | 298 | 285 | 271 | 257 |
Selling & Adminstrative & Depr. & Amort Expenses | 260 | 226 | 206 | 197 | 188 |
Income After Depreciation & Amortization | 53 | 72 | 79 | 75 | 69 |
Non-Operating Income | -24 | -2 | 5 | 4 | -1 |
Interest Expense | 19 | 15 | 12 | 13 | 13 |
Pretax Income | 11 | 54 | 72 | 66 | 56 |
Income Taxes | 9 | 21 | 23 | 12 | 22 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 2 | 33 | 49 | 54 | 34 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 2 | 33 | 49 | 54 | 34 |
Depreciation Footnote | 6/30/24 | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 91 | 107 | 112 | 108 | 102 |
Depreciation & Amortization (Cash Flow) | 37 | 35 | 33 | 33 | 33 |
Income After Depreciation & Amortization | 53 | 72 | 79 | 75 | 69 |
Earnings Per Share Data | 6/30/24 | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 |
---|---|---|---|---|---|
Average Shares | 40.52 | 40.50 | 40.50 | 40.50 | 40.50 |
Diluted EPS Before Non-Recurring Items | 1.19 | 1.21 | 1.31 | 1.24 | 1.08 |
Diluted Net EPS (GAAP) | 0.06 | 0.81 | 1.21 | 1.34 | 0.83 |
Fiscal Year end for Phibro Animal Health Corporation falls in the month of June .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 273.16 | 263.22 | 249.94 | 231.35 | 255.05 |
Cost Of Goods | 186.01 | 183.62 | 171.33 | 163.62 | 178.38 |
Gross Profit | 87.15 | 79.60 | 78.62 | 67.73 | 76.67 |
SG&A, R&D, and Dept/Amort Expenses | 68.73 | 59.68 | 62.92 | 68.45 | 52.90 |
Income After SG&A, R&D, and Dept/Amort Expenses | 18.42 | 19.92 | 15.70 | -0.72 | 23.77 |
Non-Operating Income | -7.27 | -2.43 | -7.48 | -6.69 | 2.17 |
Interest Expense | 4.74 | 4.58 | 4.66 | 4.56 | 4.50 |
Pretax Income | 6.41 | 12.92 | 3.57 | -11.98 | 21.44 |
Income Taxes | 5.66 | 4.52 | 2.29 | -3.96 | 9.94 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 0.75 | 8.41 | 1.27 | -8.02 | 11.50 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 0.75 | 8.41 | 1.27 | -8.02 | 11.50 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 40.60 | 40.50 | 40.50 | 40.50 | 40.50 |
Diluted EPS Before Non-Recurring Items | 0.41 | 0.31 | 0.33 | 0.14 | 0.38 |
Diluted Net EPS (GAAP) | 0.02 | 0.21 | 0.03 | -0.20 | 0.28 |